Mirum Pharmaceuticals
Bile acid transporter inhibitor therapeutics (volixibat and maralixibat) for rare pediatric cholestatic liver diseases
- Sector
- Biotech
- Headquarters
- FOSTER CITY, CA
- Founded
- 2018
- Latest Form D
- $68.5M, Jan 2026
- Total capital
- $139M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $139M
- 3 Form D · last Jan 2026
- 9 months since last filing
- Federal contracts
- $460K
- 2 awards · Veterans Affairs
- Rank in Biotech#233 of 4373
- Granted patents
- 6
- 34 pending · first 2022
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$68.5M
- Federal contractVeterans Affairs · Ctesi (chenodiol) 250MG Drug$228K
- Federal contractVeterans Affairs · Pharmacy Pharmaceutical Drug$232K
- Private capital raisedForm D · SEC · 2nd filing$10M
- Private capital raisedForm D · SEC · 1st filing$60.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Chris PeetzDirectorNamed in SEC Form D filings
- Christopher J. PeetzExecutive Officer, DirectorNamed in SEC Form D filings
- Ed MathersDirectorNamed in SEC Form D filings
- Edward T. MathersDirectorNamed in SEC Form D filings
- Edwin Jonathan TuckerExecutive OfficerNamed in SEC Form D filings
- Eric BjerkholtExecutive OfficerNamed in SEC Form D filings
Show all 22 people
- Ian J. ClementsExecutive OfficerNamed in SEC Form D filings
- Jonathan LeffDirectorNamed in SEC Form D filings
- Lara J. LongpreExecutive OfficerNamed in SEC Form D filings
- Laura BregeDirectorNamed in SEC Form D filings
- Laurent C. FischerDirectorNamed in SEC Form D filings
- Lon C. CardonDirectorNamed in SEC Form D filings
- Michael G. GreyDirectorNamed in SEC Form D filings
- Niall J. O'DonnellDirectorNamed in SEC Form D filings
- Pamela Jonathan VigExecutive OfficerNamed in SEC Form D filings
- Patrick HeronDirectorNamed in SEC Form D filings
- Peter RadovichExecutive OfficerNamed in SEC Form D filings
- Saira C. RamasastryDirectorNamed in SEC Form D filings
- Susan DubeExecutive OfficerNamed in SEC Form D filings
- Tiba AynechiDirectorNamed in SEC Form D filings
- Timothy WalbertDirectorNamed in SEC Form D filings
- William C. FaireyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingMethods For Treating Cholestatic PruritusUSPTOApplication 19454782
- PendingMethods For Treating CholestasisUSPTOApplication 19454909
- PendingMethods For Treating CholestasisUSPTOApplication 19349135
Show all 40 patent records
- Methods For Treating Cholestatic PruritusSep 10, 2026 · Application 19454782Pending
- Methods For Treating CholestasisSep 10, 2026 · Application 19454909Pending
- Methods For Treating CholestasisJul 2, 2026 · Application 19349135Pending
- Methods For Treating CholestasisApr 14, 2026 · US 12,599,602Granted
- Pharmaceutical Compositions Comprising Maralixibat And Uses ThereofApr 2, 2026 · Application 19174281Pending
- Methods For Treating CholestasisMar 17, 2026 · US 12,576,079Granted
- Methods For Treating CholestasisNov 27, 2025 · Application 19271591Pending
- Methods For Treating Cholestatic PruritusNov 13, 2025 · Application 19200443Pending
- Pharmaceutical Compositions Comprising Maralixibat And Uses ThereofMay 13, 2025 · US 12,296,050Granted
- Anti-HBsAg antibody for treatment of chronic hepatitis DDec 5, 2024 · Application 18679267Pending
- Pharmaceutical Compositions Comprising 2,3,4,5- Tetrahydrobenzothiepin- 1,1-DIOXIDE Derivatives And The Use ThereofNov 21, 2024 · Application 18667354Pending
- Methods For Treating CholestasisJun 13, 2024 · Application 18417725Pending
- Indazole Pyridone Compounds And Uses ThereofJun 6, 2024 · Application 18480499Pending
- Methods For Treating Progressive Familial Intrahepatic CholestasisMay 30, 2024 · Application 18382636Pending
- Maralixibat Solid Forms, Intermediates And Processes Of Making SameApr 11, 2024 · Application 18368041Pending
- Methods For Treating CholestasisMar 5, 2024 · US 11,918,578Granted
- Treatment With Ileal Bile Acid Transporter (ibat) Inhibitors For Increased Event-free Survival (efs)Jun 22, 2023 · Application 17981033Pending
- Apical Sodium-dependent Transporter Inhibitor CompositionsJun 15, 2023 · Application 17973194Pending
- METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs)May 4, 2023 · Application 17972909Pending
- Methods For Treating CholestasisNov 15, 2022 · US 11,497,745Granted
- Methods For Treating CholestasisMay 26, 2022 · Application 17430210Pending
- Methods For Increasing Growth In Pediatric Subjects Having Cholestatic Liver DiseaseMay 19, 2022 · Application 17430168Pending
- Genotype And Dose-dependent Response To An Asbti In Patients With Bile Salt Export Pump DeficiencyMay 5, 2022 · Application 17430125Pending
- Methods For Treating CholestasisJan 25, 2022 · US 11,229,647Granted
- METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs)Application 63280470Pending
- Treatment With Ileal Bile Acid Transporter (ibat) Inhibitors For Increased Event-free Survival (efs)Application 63276480Pending
- METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs)Application 63271916Pending
- Apical Sodium-dependent Transporter Inhibitor CompositionsApplication 63271857Pending
- Methods For Increasing Growth In Pediatric Subjects Having Cholestatic Liver DiseaseApplication PCTUS2020017970Pending
- Methods For Treating CholestasisApplication PCTUS2020017941Pending
- Genotype And Dose-dependent Response To An Asbti In Patients With Bile Salt Export Pump DeficiencyApplication PCTUS2020017951Pending
- Methods of Accelerating Growth using ASBTIsApplication 62932015Pending
- Genotype And Dose-dependent Response To Maralixibat In Patients With Bile Salt Export Pump DeficiencyApplication 62908431Pending
- Methods of Accelerating Growth Using ASBTIsApplication 62863904Pending
- Methods of Accelerating Growth Using ASBTIsApplication 62804523Pending
- Methods For Treating Cholestatic PruritusApplication PCTUS2025028032Pending
- Methods For Treating Cholestatic PruritusApplication 63673284Pending
- Pharmaceutical Compositions Comprising 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE Derivatives And The Use ThereofApplication PCTUS2024029906Pending
- Methods For Treating Cholestatic PruritusApplication 63646271Pending
- Methods For Treating Cholestatic PruritusApplication 63643524Pending
Related companies, and why
- BrainXell, IncSimilar federal contract value in Biotech · $516K in contracts
- VASCUMAB LLCSimilar federal contract value in Biotech · $502K in contracts
- Cocrystal Pharma, Inc.Similar federal contract value in Biotech · $498K in contracts
- ARIMA GENOMICS, INC.Similar federal contract value in Biotech · $457K in contracts
- APPLIED BIOTECHNOLOGY INSTITUTESimilar federal contract value in Biotech · $450K in contracts
- Nanode Therapeutics, Inc.Similar federal contract value in Biotech · $441K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .